Crossmark

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy

Crossref DOI link: https://doi.org/10.1186/s40425-018-0430-y

Published Online: 2018-10-30

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gambichler, Thilo http://orcid.org/0000-0001-7862-3695
Stockfleth, E.

Susok, L.
Funding

Funding for this research was provided by:

Ruhr-Universität Bochum
License Information

Text and Data Mining valid from 2018-10-30
More Information

Article History

Received: 16 August 2018

Accepted: 11 October 2018

First Online: 30 October 2018

Ethics approval and consent to participate

: Not applicable.

: Written informed consent for publication of the clinical details and clinical images was obtained from the patient. A copy of the written consent is available for review by the editor of the journal.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.